Metagenomi Inc (MGX)

$1.75 -0.04 (-2.23%)
Market Cap 67.18M
Revenue (ttm) 52.30M
Net Income (ttm) -78.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -149.25%
Debt to Equity Ratio 0.00
Volume 284,600
Avg Vol 382,608
Day's Range N/A - N/A
Shares Out 37.53M
Stochastic %K 61%
Beta 0.50
Analysts Strong Sell
Price Target $9.33

Company Profile

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensi...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 871 4880
Address:
5959 Horton Street, 7th Floor, Emeryville, United States
anachartanalyst
anachartanalyst May. 12 at 2:02 PM
$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 4:19 PM
$MGX Current Stock Price: $1.38
0 · Reply
MikeEhrmantraut
MikeEhrmantraut Apr. 22 at 2:27 PM
$MGX trash and pure management grift. Should be a university research department not a publicly traded company.
0 · Reply
Mindegap
Mindegap Apr. 20 at 7:50 PM
If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 9:51 PM
$MGX
0 · Reply
Mindegap
Mindegap Apr. 17 at 2:37 PM
$MGX Great News: $MGX created a tool that for the first time combines AAV-compatible size with therapeutic-grade editing efficiency — unlocking in vivo gene editing for tissues outside the liver that have been effectively unreachable until now. This enables next-generation editors that currently can't fit in AAV at all. Published in Nature. $PRME $BEAM
0 · Reply
DARKP00L
DARKP00L Apr. 16 at 11:06 AM
$MGX 07:05 on Apr. 16 2026 Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems #tradeideas
0 · Reply
MaskMaker
MaskMaker Apr. 14 at 10:53 PM
$AVXL $MGX $NXL $VTGN
0 · Reply
MaskMaker
MaskMaker Apr. 6 at 12:56 AM
$NXL $VTGN $AVXL $MGX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 1:02 AM
$MGX RSI: 25.41, MACD: -0.0605 Vol: 0.12, MA20: 1.47, MA50: 1.51 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on MGX
Metagenomi price target lowered to $9 from $12 at Wells Fargo

2026-05-12T10:27:58.000Z - 1 day ago

Metagenomi price target lowered to $9 from $12 at Wells Fargo

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 11, 2026, 4:05 PM EDT - 1 day ago

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi announces publication on MG119-28

2026-04-16T12:07:08.000Z - 26 days ago

Metagenomi announces publication on MG119-28

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Apr 16, 2026, 7:00 AM EDT - 27 days ago

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Apr 13, 2026, 12:15 PM EDT - 4 weeks ago

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Mar 5, 2026, 4:05 PM EST - 2 months ago

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 2 months ago

Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 23, 2026, 4:05 PM EST - 2 months ago

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Jan 12, 2026, 8:30 AM EST - 4 months ago

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Dec 1, 2025, 7:00 AM EST - 5 months ago

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 4:30 AM EST - 6 months ago

Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Nov 17, 2025, 8:00 AM EST - 6 months ago

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Metagenomi price target lowered to $7 from $11 at Chardan

2025-11-12T22:30:28.000Z - 6 months ago

Metagenomi price target lowered to $7 from $11 at Chardan

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

2025-11-11T21:11:48.000Z - 6 months ago

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Nov 11, 2025, 4:02 PM EST - 6 months ago

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Nov 11, 2025, 4:01 PM EST - 6 months ago

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Metagenomi taps Amazon's custom chips to develop gene-editing tools

Oct 22, 2025, 10:02 AM EDT - 7 months ago

Metagenomi taps Amazon's custom chips to develop gene-editing tools

AMZN

Metagenomi price target lowered to $11 from $12 at Chardan

2025-08-15T20:30:16.000Z - 9 months ago

Metagenomi price target lowered to $11 from $12 at Chardan

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Aug 11, 2025, 4:05 PM EDT - 9 months ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KALV

Metagenomi price target lowered to $16 from $20 at Wells Fargo

2025-05-14T10:21:54.000Z - 1 year ago

Metagenomi price target lowered to $16 from $20 at Wells Fargo

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025, 6:00 AM EDT - 1 year ago

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

Metagenomi reports Q1 EPS (68c), consensus (51c)

2025-05-13T20:41:15.000Z - 1 year ago

Metagenomi reports Q1 EPS (68c), consensus (51c)

Metagenomi sees cash, equivalents supporting operations into 2027

2025-05-13T20:41:07.000Z - 1 year ago

Metagenomi sees cash, equivalents supporting operations into 2027

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 1 year ago

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025, 7:00 AM EDT - 1 year ago

Metagenomi to Present at Upcoming Scientific Meetings

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

2025-04-03T10:15:28.000Z - 1 year ago

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Mar 13, 2025, 6:19 AM EDT - 1 year ago

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Metagenomi Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 1:10 PM EST - 1 year ago

Metagenomi Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Feb 11, 2025, 8:55 AM EST - 1 year ago

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Jan 16, 2025, 8:55 AM EST - 1 year ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Metagenomi Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Metagenomi Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Metagenomi Announces New Appointment to its Board of Directors

Jan 15, 2025, 8:55 AM EST - 1 year ago

Metagenomi Announces New Appointment to its Board of Directors

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Dec 11, 2024, 6:30 PM EST - 1 year ago

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Dec 9, 2024, 9:16 PM EST - 1 year ago

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Nov 23, 2024, 1:00 PM EST - 1 year ago

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Nov 22, 2024, 11:59 AM EST - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

anachartanalyst
anachartanalyst May. 12 at 2:02 PM
$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 4:19 PM
$MGX Current Stock Price: $1.38
0 · Reply
MikeEhrmantraut
MikeEhrmantraut Apr. 22 at 2:27 PM
$MGX trash and pure management grift. Should be a university research department not a publicly traded company.
0 · Reply
Mindegap
Mindegap Apr. 20 at 7:50 PM
If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 9:51 PM
$MGX
0 · Reply
Mindegap
Mindegap Apr. 17 at 2:37 PM
$MGX Great News: $MGX created a tool that for the first time combines AAV-compatible size with therapeutic-grade editing efficiency — unlocking in vivo gene editing for tissues outside the liver that have been effectively unreachable until now. This enables next-generation editors that currently can't fit in AAV at all. Published in Nature. $PRME $BEAM
0 · Reply
DARKP00L
DARKP00L Apr. 16 at 11:06 AM
$MGX 07:05 on Apr. 16 2026 Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems #tradeideas
0 · Reply
MaskMaker
MaskMaker Apr. 14 at 10:53 PM
$AVXL $MGX $NXL $VTGN
0 · Reply
MaskMaker
MaskMaker Apr. 6 at 12:56 AM
$NXL $VTGN $AVXL $MGX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 1:02 AM
$MGX RSI: 25.41, MACD: -0.0605 Vol: 0.12, MA20: 1.47, MA50: 1.51 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Acs375
Acs375 Mar. 18 at 2:01 PM
$MGX Very underrated genome editing company. If MGX-001 works well in humans next year this will shoot right up.
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Mar. 10 at 11:48 PM
$MGX nibbled
0 · Reply
Mindegap
Mindegap Mar. 10 at 4:23 PM
$MGX $PRME $CRBU
0 · Reply
I_am_retail_investor
I_am_retail_investor Mar. 10 at 3:25 PM
$MGX - volume is up!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 4:36 PM
$MGX RSI: 40.36, MACD: -0.0572 Vol: 0.09, MA20: 1.54, MA50: 1.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
I_am_retail_investor
I_am_retail_investor Feb. 5 at 5:25 PM
$MGX - nice uptick in a down market, my primary thesis here being genomic informatics is recognized (at some point) as gold-like in the modern age of AI.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 1:30 PM
$MGX Outstanding article that hits the mark on MGX's current state. So if you want to refresh your MGX insights or learn about MGX from scratch, this is a must read. https://everyticker.com/quote/MGX/analysis/metagenomi-unlocking-genetic-potential-with-a-deep-toolbox-nasdaq-mgx
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 30 at 1:25 AM
$MGX RSI: 32.08, MACD: -0.0344 Vol: 0.06, MA20: 1.69, MA50: 1.69 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
AdiDasRom
AdiDasRom Jan. 16 at 7:39 PM
$MGX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 10:54 AM
$MGX RSI: 44.93, MACD: -0.0640 Vol: 0.07, MA20: 1.71, MA50: 1.92 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Jan. 4 at 7:48 PM
$MGX A quick summary for MGX https://substack.com/profile/160232761-biotech-pharma-investor/note/c-195232298?r=2nece1
0 · Reply
Bayesed
Bayesed Dec. 31 at 1:12 PM
$OTLK I remember when Sam Altman stood next to Trump in the White House for the Stargate project, and he mentioned MGX, a Gulf investment fund, and $MGX went flying pre-market. I expect something similar happened here, as few people knew about $CORT and immediately thought the rejection was for $OTLK Some investors should be away from the market
0 · Reply